Drug giant Pfizer is starting 20 clinical trials this year and more soon after on cancer treatments, aiming to be a leader in the hot, lucrative field.
Continue Reading Below
A decade ago, Pfizer wasn't even a player in cancer research. Today, Pfizer has eight approved cancer medicines. It's running late-stage patient tests on five of those drugs for additional uses, has three other drugs in late-stage testing and has 14 other cancer drug development programs in early stages.
Pfizer executives say their technology, in-house expertise and partnerships with university researchers and other drugmakers position the company uniquely to create the best drug combinations and become a leader in cancer medicine.
Its programs include drugs designed to kill tumor cells and other treatments that stimulate the immune system to mount a stronger defense.